Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.63 Bil Enterprise Value: 14.68 Bil PE Ratio: 71.95 PB Ratio: 2.88 GF Score: 71/100

Biomarin Pharmaceutical Inc at Piper Sandler Healthcare Conference (Virtual) Transcript

Dec 02, 2020 / 08:00PM GMT
Release Date Price: $78.76
Christopher Joseph Raymond
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. Great. Well, let's go ahead and get started with our next session. Thanks, everybody, for dialing in. My name is Chris Raymond. I'm one of Piper Sandler's biotech analysts. And very pleased to have with us our next presenter and company for our fireside chat format here, BioMarin. We're lucky to have with us the full complement of the management team here. We have CEO and Chairman, J.J. Bienaimé; President of Worldwide R&D, Hank Fuchs; and Brian Mueller, who is the CFO.

So as is the format that we've done in the past, we'll be -- this will be a fireside chat format. But just to maybe level set the story for investors, maybe for the few who might not necessarily know the story. J.J., if you wouldn't mind giving us a 2- to 3-minute or so intro on BioMarin, that would be great, and then we'll dive into the Q&A.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Yes. Thank you, Chris. Thank you for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot